Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial)
Objective: Phase I multicenter study defined the maximal tolerated dose (MTD), dose-limiting toxicity (DLT) and safety profile of capecitabine in combination with preoperative radiation for patients with locally advanced rectal cancer (LARC). Material and Method: Patients were treated with oral cape...
Saved in:
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-33845495420&partnerID=40&md5=31aee1aa06e324d9dc4b8648a1d6bbd4 http://cmuir.cmu.ac.th/handle/6653943832/2017 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
id |
th-cmuir.6653943832-2017 |
---|---|
record_format |
dspace |
spelling |
th-cmuir.6653943832-20172014-08-30T02:00:23Z Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) Veerasarn V. Phromratanapongse P. Lorvidhaya V. Lertsanguansinchai P. Lertbutsayanukul C. Panichevaluk A. Boonnuch W. Chinswangwatanakul V. Lohsiriwat D. Rojanasakul A. Thavichaigarn P. Jivapaisarnpong P. Objective: Phase I multicenter study defined the maximal tolerated dose (MTD), dose-limiting toxicity (DLT) and safety profile of capecitabine in combination with preoperative radiation for patients with locally advanced rectal cancer (LARC). Material and Method: Patients were treated with oral capecitabine (700, 800, 900, 1000, 1100 and 1200 mg/ m2 twice daily continuously) plus preoperative whole pelvic irradiation (45-46 Gy in 23-25 fractions over 5-6 weeks). Surgery was performed at the median of 42 days after chemoradiation treatment. Results: Twenty-seven patients were in this trial. Eighteen patients (3 per dose level) had received capecitabine from 700 mg/m2 twice daily to the highest dose level of 1200 mg/m2 twice daily. There were no grade 3/4 DLTs during dose escalation, a further nine patients were included at the highest capecitabine dose. Two of the twelve patients (16%) receiving capecitabine 1200 mg/m2 twice daily developed grade 3 diarrhea and discontinued treatment. There were no other grade 3/4 adverse events. After capecitabine chemoradiation, 24 of 27 patients (89%) received definite surgery. Primary and lymph node down staging occurred in ten patients (42%). Sphincter-sparing surgery was performed in seven patients (26%) and abdominal-perineal resection was performed in 17 patients (63%). Conclusion: Preoperative capecitabine chemoradiation based on continuous daily capecitabine is very well tolerated in patients with LARC. The authors did not reach the MTD in the present study. 2014-08-30T02:00:23Z 2014-08-30T02:00:23Z 2006 Article 01252208 17205868 JMTHB http://www.scopus.com/inward/record.url?eid=2-s2.0-33845495420&partnerID=40&md5=31aee1aa06e324d9dc4b8648a1d6bbd4 http://cmuir.cmu.ac.th/handle/6653943832/2017 English |
institution |
Chiang Mai University |
building |
Chiang Mai University Library |
country |
Thailand |
collection |
CMU Intellectual Repository |
language |
English |
description |
Objective: Phase I multicenter study defined the maximal tolerated dose (MTD), dose-limiting toxicity (DLT) and safety profile of capecitabine in combination with preoperative radiation for patients with locally advanced rectal cancer (LARC). Material and Method: Patients were treated with oral capecitabine (700, 800, 900, 1000, 1100 and 1200 mg/ m2 twice daily continuously) plus preoperative whole pelvic irradiation (45-46 Gy in 23-25 fractions over 5-6 weeks). Surgery was performed at the median of 42 days after chemoradiation treatment. Results: Twenty-seven patients were in this trial. Eighteen patients (3 per dose level) had received capecitabine from 700 mg/m2 twice daily to the highest dose level of 1200 mg/m2 twice daily. There were no grade 3/4 DLTs during dose escalation, a further nine patients were included at the highest capecitabine dose. Two of the twelve patients (16%) receiving capecitabine 1200 mg/m2 twice daily developed grade 3 diarrhea and discontinued treatment. There were no other grade 3/4 adverse events. After capecitabine chemoradiation, 24 of 27 patients (89%) received definite surgery. Primary and lymph node down staging occurred in ten patients (42%). Sphincter-sparing surgery was performed in seven patients (26%) and abdominal-perineal resection was performed in 17 patients (63%). Conclusion: Preoperative capecitabine chemoradiation based on continuous daily capecitabine is very well tolerated in patients with LARC. The authors did not reach the MTD in the present study. |
format |
Article |
author |
Veerasarn V. Phromratanapongse P. Lorvidhaya V. Lertsanguansinchai P. Lertbutsayanukul C. Panichevaluk A. Boonnuch W. Chinswangwatanakul V. Lohsiriwat D. Rojanasakul A. Thavichaigarn P. Jivapaisarnpong P. |
spellingShingle |
Veerasarn V. Phromratanapongse P. Lorvidhaya V. Lertsanguansinchai P. Lertbutsayanukul C. Panichevaluk A. Boonnuch W. Chinswangwatanakul V. Lohsiriwat D. Rojanasakul A. Thavichaigarn P. Jivapaisarnpong P. Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
author_facet |
Veerasarn V. Phromratanapongse P. Lorvidhaya V. Lertsanguansinchai P. Lertbutsayanukul C. Panichevaluk A. Boonnuch W. Chinswangwatanakul V. Lohsiriwat D. Rojanasakul A. Thavichaigarn P. Jivapaisarnpong P. |
author_sort |
Veerasarn V. |
title |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
title_short |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
title_full |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
title_fullStr |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
title_full_unstemmed |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial) |
title_sort |
preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase i trial) |
publishDate |
2014 |
url |
http://www.scopus.com/inward/record.url?eid=2-s2.0-33845495420&partnerID=40&md5=31aee1aa06e324d9dc4b8648a1d6bbd4 http://cmuir.cmu.ac.th/handle/6653943832/2017 |
_version_ |
1681419779130261504 |